Last reviewed · How we verify
NeuVax™ vaccine
NeuVax™ vaccine is a Therapeutic cancer vaccine Biologic drug developed by Galena Biopharma, Inc.. It is currently in Phase 3 development for HER2-positive breast cancer (adjuvant setting, Phase 3). Also known as: E75 peptide acetate , WFI, sargramostim, GM-CSF, E75 peptide (KIFGSLAFL, HER2/neu, 369-377), GM-CSF (sargramostim), nelipepimut-S.
NeuVax is a therapeutic cancer vaccine that stimulates the immune system to recognize and attack cancer cells expressing the HER2 protein.
NeuVax is a therapeutic cancer vaccine that stimulates the immune system to recognize and attack cancer cells expressing the HER2 protein. Used for HER2-positive breast cancer (adjuvant setting, Phase 3).
At a glance
| Generic name | NeuVax™ vaccine |
|---|---|
| Also known as | E75 peptide acetate , WFI, sargramostim, GM-CSF, E75 peptide (KIFGSLAFL, HER2/neu, 369-377), GM-CSF (sargramostim), nelipepimut-S |
| Sponsor | Galena Biopharma, Inc. |
| Drug class | Therapeutic cancer vaccine |
| Target | HER2 (human epidermal growth factor receptor 2) |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
NeuVax uses a peptide-based immunotherapy approach designed to activate T-cell responses against HER2-positive tumors. The vaccine contains a HER2-derived peptide (E75) combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) to enhance immune activation. This approach aims to prevent recurrence in patients with HER2-positive breast cancer by training the immune system to target residual cancer cells.
Approved indications
- HER2-positive breast cancer (adjuvant setting, Phase 3)
Common side effects
- Injection site reactions
- Fatigue
- Fever
- Myalgia
Key clinical trials
- Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients (PHASE2)
- Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NeuVax™ vaccine CI brief — competitive landscape report
- NeuVax™ vaccine updates RSS · CI watch RSS
- Galena Biopharma, Inc. portfolio CI
Frequently asked questions about NeuVax™ vaccine
What is NeuVax™ vaccine?
How does NeuVax™ vaccine work?
What is NeuVax™ vaccine used for?
Who makes NeuVax™ vaccine?
Is NeuVax™ vaccine also known as anything else?
What drug class is NeuVax™ vaccine in?
What development phase is NeuVax™ vaccine in?
What are the side effects of NeuVax™ vaccine?
What does NeuVax™ vaccine target?
Related
- Drug class: All Therapeutic cancer vaccine drugs
- Target: All drugs targeting HER2 (human epidermal growth factor receptor 2)
- Manufacturer: Galena Biopharma, Inc. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for HER2-positive breast cancer (adjuvant setting, Phase 3)
- Also known as: E75 peptide acetate , WFI, sargramostim, GM-CSF, E75 peptide (KIFGSLAFL, HER2/neu, 369-377), GM-CSF (sargramostim), nelipepimut-S
- Compare: NeuVax™ vaccine vs similar drugs
- Pricing: NeuVax™ vaccine cost, discount & access